Article III Standing for an IPR Appeal Despite Patent Expiration and No Pending Litigation

June 4, 2019

Another Biosimilar Receives FDA Approval and Is Confronted with Litigation

May 28, 2019

Jury Finds Amgen Antibody Patents Not Invalid

March 18, 2019

Business as Usual for the USPTO and Federal Circuit Under the Partial Government Shutdown, At Least for Now

January 23, 2019

RFEM’s Biosimilars Inter Partes Review (IPR) Dashboard

November 14, 2018

PTAB Exercises its § 325(d) Discretion to Deny IPR of Piglet Vaccine Patent

November 5, 2018

USPTO Issues an Update to the AIA Trial Practice Guide

August 29, 2018

Litigation vs. Licensing: Manufacturers of the Two Most Recently Approved Biosimilars Take Different Approaches to Reference Drug Patents

December 5, 2017

PTAB Issues First PGR Institution Decisions in Months

October 24, 2017

Reissue Applications During Post Grant Proceedings: To Stay or Not to Stay?

October 4, 2017